NCT04235114View on ClinicalTrials.gov

Evaluation of 89Zr-DFO-nimotuzumab for Non-invasive Imaging of EGFR+ Cancers by Positron Emission Tomography (PET)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

February 1, 2020

Primary Completion Date

September 30, 2026

Study Completion Date

December 31, 2026

Conditions
Lung CancerColorectal Cancer
Interventions
DRUG

50 mg 89Zr-DFO-Nimotuzumab

A maximum of 2 mCi (range 1 - 2 mCi) 50 mg of 89Zr-DFO-nimotuzumab will be injected intravenously over a period of at 2 - 3 minutes. Injection will be followed by a normal saline flush of 20-30 mL. PET/CT scan will be done at different time points post infusion.

DRUG

1 mg 89Zr-DFO-Nimotuzumab

A maximum of 2 mCi (range 1 - 2 mCi) 1 mg of 89Zr-DFO-nimotuzumab will be injected intravenously over a period of at 2 - 3 minutes. Injection will be followed by a normal saline flush of 20-30 mL. PET/CT scan will be done at different time points post infusion.

Trial Locations (1)

Unknown

RECRUITING

Royal University Hospital, Saskatoon

All Listed Sponsors
lead

University of Saskatchewan

OTHER

NCT04235114 - Evaluation of 89Zr-DFO-nimotuzumab for Non-invasive Imaging of EGFR+ Cancers by Positron Emission Tomography (PET) | Biotech Hunter | Biotech Hunter